This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;284:2711.

	Since this article does not have an abstract, we have provided the first 96 words of the full text and any section headings.

The US Pharmacopeia (USP) has ceased operating its Drug Product Problem Reporting Program, which enabled pharmacists and other health care professionals to report drug quality problems "so that its efforts an resources may be concentrated on medication error reporting and prevention." The FDA wishes to encourage those who used the USP program to report product quality problems as well as adverse medical events to MEDWATCH by phone ([800] FDA-1088), fax ([800] FDA-0178), mail (MEDWATCH, FDA, HF-2, 5600 Fishers Ln, Rockville, MD 20857), or online (http://www.accessdata.fda.gov/scripts/medwatch).

AUTHOR INFORMATION

Written inquiries may be directed to Jane E. Henney, MD, Commissioner of Food and Drugs, HF-1, Room 14-71, 5600 Fishers Ln, Rockville, MD 20857.

Jane E. Henney, MD
Commissioner of Food and Drugs

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Electrohydraulic High-Energy Shock-Wave Treatment for Chronic Plantar Fasciitis
Ogden et al.
JBJS 2004;86:2216-2228.
ABSTRACT | FULL TEXT